Recombinant Human CD32b (C-6His)(Cat. No.:C444) novoprotein
$80.00
In stock
SKU
C444
10μg: $80
50μg: $220
500μg: $1540
1mg: $2200
Description
Recombinant Human Low Affinity Immunoglobulin Gamma Fc Region Receptor II-B is produced by our Mammalian expression system and the target gene encoding Thr43-Pro217 is expressed with a 6His tag at the C-terminus.
Product Details
| Item | Details |
| Known As | Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b; IgG Fc Receptor II-b; CDw32; Fc-Gamma RII-b; Fc-Gamma-RIIb; FcRII-b; CD32; FCGR2B; FCG2; IGFR2 |
| Mol Mass | 20.64 KDa |
| APMol Mass | 22-30 KDa, reducing conditions |
| Formulation Description | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
| Endotoxin | < 1 EU/µg as determined by LAL test. |
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
| Storage | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
Background
FcγRIIB is a low affinity receptor that recognizes the Fc portion of IgG. The human CD32 group consists of FcγRIIA, FcγRIIB, and FcγRIIC proteins that share 94-99% sequence identity in their extracellular domains but differ substantially in their transmembrane and cytoplasmic domains. FcγRII protein is expressed on cells of both myeloid and lymphoid lineages as well as on cells of non-hematopoietic origin. FcγRIIB has an intrinsic cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and delivers an inhibitory signal upon ligand binding. Ligation of FcγRIIB on B cells down-regulates antibody production and in some circumstances may promote apoptosis. Co-ligation of FcγRIIB on dendritic cells inhibits maturation and blocks cell activation. FcγRIIB may also be a target for monoclonal antibody therapy for malignancies. FcγRIIB plays an important negative-regulating role through modulating the signals from activation receptors.
title: Construction of a novel B7H3 VHH-Fc antibody with potent antitumor activity and NK/T cell activation
authors: Ailing Pan, Caiyi Yuan, Yaru Wang, Chengcheng Qiu, Guojian Liu, Min Pei, Huanhuan Li, Santai Li, Yili Chen, Chunhe Wang
date: 2026/03/10
journal: PROTEIN EXPRESSION AND PURIFICATION
title: Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers
authors: Amin Ladan, Harris David A.
date: 2021
journal: Nature Communications
MDSD
Reviews
Write Your Own Review